Pfizer Inc. has entered into a definitive exclusive licensing agreement with Starna Therapeutics, a Suzhou-based biotechnology firm specializing in RNA-based medicines, to develop and commercialize three preclinical in-vivo Chimeric Antigen Receptor T-cell (CAR-T) programs. Under the terms of the agreement, Pfizer will provide an upfront payment of $330 million to Starna for global rights to these programs, excluding Greater China. The deal carries a total potential value of $2.3 billion in additional payments contingent upon the achievement of specific development and commercial milestones, alongside tiered royalties on future sales. This strategic move signals Pfizer’s aggressive entry into the next generation of cell therapy, pivoting from the complex and costly "ex-vivo" methods that defined the first wave of the industry toward a more scalable "in-vivo" approach.
The Shift from Ex-Vivo to In-Vivo Cell Therapy
The landscape of cell therapy has undergone a radical transformation since the first CAR-T treatments received regulatory approval nearly a decade ago. Traditional CAR-T therapies, such as those used in oncology, utilize an ex-vivo manufacturing process. This involves extracting a patient’s T-cells through leukapheresis, transporting them to a specialized laboratory, genetically engineering them to recognize cancer or disease markers, and then re-infusing them into the patient after a regimen of lymphodepleting chemotherapy.
While highly effective, this process is fraught with logistical challenges, including high manufacturing costs—often exceeding $400,000 per dose—long turnaround times that can last weeks, and significant patient burden. Furthermore, the infrastructure required for such "personalized" medicine has limited its reach to major academic medical centers.
The partnership between Pfizer and Starna Therapeutics focuses on the emerging "in-vivo" paradigm. In this model, the genetic reprogramming of immune cells occurs directly within the patient’s body. By delivering a messenger RNA (mRNA) payload via lipid nanoparticles (LNPs), the therapy instructs the patient’s internal T-cells to express the Chimeric Antigen Receptor. This eliminates the need for external manufacturing, reduces the time to treatment from weeks to days, and potentially lowers the cost of therapy to a fraction of the current price point. For Pfizer, this transition represents a logical evolution of the mRNA expertise it cultivated during the development of Comirnaty, its COVID-19 vaccine produced in partnership with BioNTech.
Technical Innovations: Overcoming the "Liver Trap"
A primary technical hurdle in the development of in-vivo mRNA therapies has been the delivery mechanism. Historically, lipid nanoparticles (LNPs) have a natural affinity for the liver, as they are cleared by the hepatic system. This "liver trap" has made it difficult to target other organs or specific cell types, such as the T-cells located in the spleen or lymph nodes, which are essential for CAR-T therapy.
Starna Therapeutics has developed a proprietary LNP technology platform designed to bypass the liver and achieve extra-hepatic delivery. By engineering the chemical composition of the lipid envelope, Starna’s technology can direct the RNA payload to specific immune cells. This precision is critical for autoimmune applications, where the goal is often to create regulatory T-cells (Tregs) or to deplete B-cells that are driving an overactive immune response.
The agreement grants Pfizer access to this technology not only for the three initial autoimmune programs but also for broader applications in inflammation, immunology, and oncology. While the specific targets of the three programs remain undisclosed, industry analysts suggest they likely focus on high-prevalence conditions such as systemic lupus erythematosus (SLE), myasthenia gravis, or refractory rheumatoid arthritis, where current biologic treatments often fail to provide long-term remission.
Strategic Context: Pfizer’s Immunology Pipeline and the "Patent Cliff"
Pfizer’s investment in Starna Therapeutics comes at a critical juncture for the pharmaceutical giant. The company’s flagship immunology drug, Xeljanz (tofacitinib), a JAK inhibitor approved for various inflammatory conditions, has historically been a blockbuster performer. However, Xeljanz is facing the expiration of key patents, which will inevitably lead to generic competition and a decline in revenue.
To offset these losses, Pfizer is diversifying its portfolio with high-value, complex therapeutics that are harder to replicate. Michael Vincent, Pfizer’s Chief Inflammation & Immunology Officer, emphasized that in-vivo CAR-T represents a "promising approach for treating autoimmune diseases" particularly for patients "for whom today’s options fall short." By securing Starna’s assets, Pfizer is positioning itself to lead a market segment that could redefine the standard of care for chronic immune disorders.

A Chronology of the In-Vivo CAR-T Arms Race
The Pfizer-Starna deal is the latest in a series of high-stakes transactions as major pharmaceutical companies race to secure a foothold in the in-vivo space. The year 2024 and late 2023 have seen a flurry of activity in this sector:
- Eli Lilly: Acquired or partnered with firms like Orna Therapeutics to explore circular RNA and in-vivo delivery for autoimmune indications.
- Johnson & Johnson: Formed a collaboration with Sail Biomedicines to develop in-vivo CAR-T therapies aimed at "resetting" the immune system.
- AbbVie: Entered into an agreement with Capstan Immunology, focusing on in-vivo CAR-T for immunology and inflammation.
- AstraZeneca: Acquired EsoBiotic to bolster its allogeneic and in-vivo cell therapy capabilities.
- Bristol Myers Squibb: Partnered with Orbital Therapeutics to leverage their RNA platform for in-vivo applications in autoimmune diseases.
- Gilead Sciences: Through its subsidiary Kite, acquired Interius Biotherapeutics to focus on in-vivo delivery for cancer and autoimmune conditions.
This trend indicates a collective industry belief that the future of cell therapy lies in "off-the-shelf" or in-vivo solutions that can be administered in a standard clinical setting, rather than the bespoke, centralized laboratory model of the past.
Clinical Development and Global Manufacturing Logistics
Under the agreement, Pfizer will take the lead in clinical development for the Starna programs outside of Greater China. A significant component of this partnership is Pfizer’s commitment to utilizing its existing U.S.-based manufacturing facilities. The company noted that it plans to handle the production of the drug candidates for clinical trials internally, leveraging the massive RNA manufacturing infrastructure it built during the pandemic.
This vertical integration provides Pfizer with a competitive advantage in terms of quality control and supply chain stability. Starna Therapeutics retains the rights to develop and commercialize these therapies in Greater China, a region that has become a global hub for cell therapy research and clinical trials. However, the deal includes an option for Pfizer to expand its territory to include Greater China in the future, should the programs prove successful in early-stage trials.
Market Implications and Potential for "Functional Cures"
The application of CAR-T to autoimmune diseases is considered one of the most exciting frontiers in modern medicine. Unlike traditional immunosuppressants, which require lifelong administration and can leave patients vulnerable to infections, CAR-T therapy offers the potential for a "functional cure." In early academic trials, CAR-T cells have been shown to "reset" the immune system in lupus patients, leading to drug-free remission that lasts for years.
If Pfizer and Starna can successfully translate these academic findings into a scalable in-vivo product, the economic impact would be substantial. The global market for autoimmune disease treatments is projected to exceed $150 billion by the end of the decade. A therapy that offers long-term remission with a single or limited number of doses would disrupt the current treatment model of chronic, daily medication.
Challenges and Future Outlook
Despite the significant investment and technological promise, the path forward is not without risks. In-vivo CAR-T is still in the preclinical stage, and the transition from animal models to human patients often reveals unforeseen safety or efficacy hurdles. Specifically, the "off-target" effects—where the RNA payload is delivered to the wrong cells—could lead to systemic toxicity or unintended immune responses.
Furthermore, the regulatory pathway for in-vivo cell therapies is still being defined. The FDA and other global regulators will likely require extensive data on the long-term persistence of the engineered cells and the potential for genomic integration, even though mRNA-based approaches are generally non-integrating and transient.
The Pfizer-Starna collaboration represents a high-conviction bet on the convergence of RNA technology and cell therapy. By combining Starna’s specialized LNP delivery platform with Pfizer’s global clinical and manufacturing scale, the partnership aims to move cell therapy out of the specialized oncology ward and into the broader realm of chronic disease management. As clinical trials commence in the coming years, the industry will be watching closely to see if this "next generation" of medicine can deliver on its promise of accessible, curative treatments for the millions of patients living with autoimmune conditions.
